医学
优势比
甲硝唑
怀孕
置信区间
产科
前瞻性队列研究
荟萃分析
孕早期
妇科
妊娠期
内科学
抗生素
遗传学
微生物学
生物
作者
P Burtin,Anna Taddio,Omer Ariburnu,Thomas R. Einarson,Gideon Koren
标识
DOI:10.1016/0002-9378(95)90567-7
摘要
Our purpose was to determine from published experience in humans whether metronidazole exposure during the first trimester of pregnancy is associated with an increased teratogenic risk.All published articles reporting on metronidazole use during pregnancy were screened by two independent reviewers to select those including pregnant patients exposed during the first trimester and comparing the outcomes of their pregnancies with that of patients either not exposed to metronidazole or exposed only during the third trimester. The outcome under consideration was the occurrence of birth defects in live-born infants. The overall odds ratios of first-trimester exposure versus no first-trimester exposure was calculated by combining the selected studies in a meta-analysis according to the procedure of Mantel and Haenszel.From 32 identified studies, 7 met the inclusion criteria for meta-analysis. Six were prospective and included 253 women exposed to the drug in the first trimester of pregnancy; one was retrospective and reported on 1083 exposed women. The overall weighted odds ratio of exposure versus no exposure during the first trimester calculated by meta-analysis of the 7 studies was 0.93 (95% confidence interval 0.73 to 1.18). The odds ratio calculated from the 6 prospective studies was 1.02 (95% confidence interval 0.48 to 2.18).Metronidazole does not appear to be associated with an increased teratogenic risk.
科研通智能强力驱动
Strongly Powered by AbleSci AI